AVBP ArriVent BioPharma, Inc. Common Stock
USHealthcareAs of 2026-07-08 16:00
Why AVBP matters now
ArriVent BioPharma, Inc. Common Stock (AVBP) is a US stock in Healthcare. The latest InvestLog snapshot shows $33.40 with -2.28% on the session and $1.56B in market capitalization; recent performance reads 1-month +21.38% and YTD +57.75%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-43.3M, and EPS of $-0.96. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.1%.
The latest indexable market news headline is "ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $45.00; recent insider activity includes Kastenmayer James Paul filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.42
P/S
0.00
EV/EBITDA
-9.75
DCF Value
$1.05
FCF Yield
-9.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-49.0%
ROA
-41.6%
ROIC
-48.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-43.3M | $-0.96 |
| Q4 2025 | $0.00 | $-35.5M | $-0.84 |
| FY 2025 | $0.00 | $-166.3M | $-4.32 |
| Q3 2025 | $0.00 | $-35.0M | $-0.83 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$45.00
Target (Median)
$45.00
Target Range
$45.00 - $45.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.42
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, advancing, and bringing to market treatments addressing critical gaps in cancer patient care. The company specifically focuses on developing and commercializing targeted oncology therapies for conditions like non-small-cell lung cancer (NSCLC) and various solid tumor indications. Among its pipeline candidates are Furmonertinib, an epidermal growth factor receptor (EGFR) mutant-selective tyrosine kinase inhibitor currently undergoing a Phase 3 clinical trial for NSCLC treatment, and ARR-002. ArriVent maintains strategic alliances, including one with Aarvik Therapeutics Inc. Established in 2021, its operations are headquartered in Newtown Square, Pennsylvania.